Tags

Type your tag names separated by a space and hit enter

[Treatment of ankylosing spondylitis and undifferentiated spondyloarthritis with TNF alpha-antagonists].
Z Rheumatol. 2003 Jun; 62(3):218-27.ZR

Abstract

The spondyloarthritides (SpA) are common inflammatory rheumatic diseases with an overall prevalence of 0.6-1.9%. Ankylosing spondylitis (AS) and undifferentiated spondyloarthritis (uSpA) are the most common subsets of SpA. Women are almost as frequently affected as men, but the total burden of disease may be similar. At least one third of AS patients are severely affected with impaired function and a poor quality of life similar to patients with rheumatoid arthritis. However, AS starts 20-30 years earlier in life. Thus, AS has a relevant socioeconomic impact on society. After decades of no progress concerning treatment options in SpA, there is now accumulating evidence that the new anti-TNF alpha agents do not only reduce signs and symptoms of AS caused by inflammation but they may also diminish structural damage. Very recent magnetic resonance imaging (MRI) data of a follow-up study support this assumption. The following paper reviews the currently available literature on anti-TNF alpha therapy in AS and uSpA. Efficacy, side effects and experiences with different doses are discussed. In expectation of the approval of infliximab and etanercept for the treatment of active AS international guidelines for initiation, monitoring and discontinuation of these agents have been recently proposed.

Authors+Show Affiliations

Rheumazentrum Ruhrgebiet, Landgrafenstr. 15, 44652 Herne, Germany. J.Braun@rheumazentrum-ruhrgebiet.deNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

ger

PubMed ID

12827397

Citation

Brandt, J, et al. "[Treatment of Ankylosing Spondylitis and Undifferentiated Spondyloarthritis With TNF Alpha-antagonists]." Zeitschrift Fur Rheumatologie, vol. 62, no. 3, 2003, pp. 218-27.
Brandt J, Sieper J, Braun J. [Treatment of ankylosing spondylitis and undifferentiated spondyloarthritis with TNF alpha-antagonists]. Z Rheumatol. 2003;62(3):218-27.
Brandt, J., Sieper, J., & Braun, J. (2003). [Treatment of ankylosing spondylitis and undifferentiated spondyloarthritis with TNF alpha-antagonists]. Zeitschrift Fur Rheumatologie, 62(3), 218-27.
Brandt J, Sieper J, Braun J. [Treatment of Ankylosing Spondylitis and Undifferentiated Spondyloarthritis With TNF Alpha-antagonists]. Z Rheumatol. 2003;62(3):218-27. PubMed PMID: 12827397.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Treatment of ankylosing spondylitis and undifferentiated spondyloarthritis with TNF alpha-antagonists]. AU - Brandt,J, AU - Sieper,J, AU - Braun,J, PY - 2003/6/27/pubmed PY - 2004/1/30/medline PY - 2003/6/27/entrez SP - 218 EP - 27 JF - Zeitschrift fur Rheumatologie JO - Z Rheumatol VL - 62 IS - 3 N2 - The spondyloarthritides (SpA) are common inflammatory rheumatic diseases with an overall prevalence of 0.6-1.9%. Ankylosing spondylitis (AS) and undifferentiated spondyloarthritis (uSpA) are the most common subsets of SpA. Women are almost as frequently affected as men, but the total burden of disease may be similar. At least one third of AS patients are severely affected with impaired function and a poor quality of life similar to patients with rheumatoid arthritis. However, AS starts 20-30 years earlier in life. Thus, AS has a relevant socioeconomic impact on society. After decades of no progress concerning treatment options in SpA, there is now accumulating evidence that the new anti-TNF alpha agents do not only reduce signs and symptoms of AS caused by inflammation but they may also diminish structural damage. Very recent magnetic resonance imaging (MRI) data of a follow-up study support this assumption. The following paper reviews the currently available literature on anti-TNF alpha therapy in AS and uSpA. Efficacy, side effects and experiences with different doses are discussed. In expectation of the approval of infliximab and etanercept for the treatment of active AS international guidelines for initiation, monitoring and discontinuation of these agents have been recently proposed. SN - 0340-1855 UR - https://www.unboundmedicine.com/medline/citation/12827397/[Treatment_of_ankylosing_spondylitis_and_undifferentiated_spondyloarthritis_with_TNF_alpha_antagonists]_ L2 - https://dx.doi.org/10.1007/s00393-003-0518-7 DB - PRIME DP - Unbound Medicine ER -